SG11202007218YA - Process for the preparation of galnac oligonucleotide conjugates - Google Patents

Process for the preparation of galnac oligonucleotide conjugates

Info

Publication number
SG11202007218YA
SG11202007218YA SG11202007218YA SG11202007218YA SG11202007218YA SG 11202007218Y A SG11202007218Y A SG 11202007218YA SG 11202007218Y A SG11202007218Y A SG 11202007218YA SG 11202007218Y A SG11202007218Y A SG 11202007218YA SG 11202007218Y A SG11202007218Y A SG 11202007218YA
Authority
SG
Singapore
Prior art keywords
preparation
oligonucleotide conjugates
galnac oligonucleotide
galnac
conjugates
Prior art date
Application number
SG11202007218YA
Inventor
Simon Breitler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202007218YA publication Critical patent/SG11202007218YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08Polyoxyalkylene derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11202007218YA 2018-01-29 2019-01-28 Process for the preparation of galnac oligonucleotide conjugates SG11202007218YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18153875 2018-01-29
PCT/EP2019/052014 WO2019145543A1 (en) 2018-01-29 2019-01-28 Process for the preparation of galnac oligonucleotide conjugates

Publications (1)

Publication Number Publication Date
SG11202007218YA true SG11202007218YA (en) 2020-08-28

Family

ID=61163487

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007218YA SG11202007218YA (en) 2018-01-29 2019-01-28 Process for the preparation of galnac oligonucleotide conjugates

Country Status (12)

Country Link
US (1) US11339187B2 (en)
EP (1) EP3746131A1 (en)
JP (1) JP2021512082A (en)
KR (1) KR20200113206A (en)
CN (1) CN111699007A (en)
AU (1) AU2019213004B2 (en)
BR (1) BR112020013431A2 (en)
CA (1) CA3088066A1 (en)
IL (1) IL276043B1 (en)
MX (1) MX2020007915A (en)
SG (1) SG11202007218YA (en)
WO (1) WO2019145543A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45496A (en) 2016-06-17 2019-04-24 Hoffmann La Roche NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
KR102431353B1 (en) 2017-10-16 2022-08-10 에프. 호프만-라 로슈 아게 NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
WO2020007892A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2539451T1 (en) * 2010-02-24 2016-04-29 Arrowhead Research Corporation Compositions for targeted delivery of sirna
AU2015329974B2 (en) * 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
EP4026568A1 (en) * 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
SI3331892T1 (en) * 2015-08-06 2019-10-30 Hoffmann La Roche Processes for the preparation of galnac acid derivatives
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates

Also Published As

Publication number Publication date
JP2021512082A (en) 2021-05-13
CA3088066A1 (en) 2019-08-01
EP3746131A1 (en) 2020-12-09
CN111699007A (en) 2020-09-22
BR112020013431A2 (en) 2020-12-01
WO2019145543A1 (en) 2019-08-01
IL276043B1 (en) 2024-02-01
AU2019213004A1 (en) 2020-07-16
US20200361983A1 (en) 2020-11-19
AU2019213004B2 (en) 2024-03-07
US11339187B2 (en) 2022-05-24
IL276043A (en) 2020-08-31
KR20200113206A (en) 2020-10-06
MX2020007915A (en) 2020-09-03

Similar Documents

Publication Publication Date Title
IL276917A (en) Process for the preparation of elobixibat
IL276043A (en) Process for the preparation of galnac oligonucleotide conjugates
PL3630848T3 (en) Process for galnac oligonucleotide conjugates
IL273137A (en) Galnac derivatives
GB2593352B (en) Process for the preparation of 3alpha-hydroxy-5alpha-pregnan-20-one (brexanolone)
IL260465B (en) Process for the preparation of an antibody-rifamycin conjugate
EP3694499A4 (en) Novel process for the preparation of lifitegrast
HUE057703T2 (en) Process for the preparation of polysaccharides
IL270177B (en) Process for the preparation of deuterated ethanol from d2
IL288116A (en) Process for the preparation of galnac phosphoramidite epimers
HUE063118T2 (en) Process for the preparation of n-alkyl-nitratoethylnitramines
IL281254A (en) Process for the preparation of lenvatinib
IL274757A (en) Process for the preparation of drug linker compounds
IL275480A (en) Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
IL268835B (en) Process for the preparation of 2-cyanoimidazole compounds
EP3612167A4 (en) Process for preparing an oral disintegrating dosage form
IL289904A (en) Process for the preparation of biphenylamines
IL279410A (en) Process for the preparation of quinmerac
EP3877361C0 (en) Process for the preparation of arylsulfonylpropenenitriles
PL3599256T3 (en) Process for the preparation of polyorganosiloaxnes
HUP1800278A2 (en) Process for the preparation of boc-linagliptin
IL274560A (en) Process for the preparation of raltegravir
IL289440A (en) Process for the deprotection of oligonucleotides
IL274487A (en) Process for the preparation of fluopicolide
GB201815836D0 (en) Nucleic acid conjugates